Why the study?
Does immunization with EMCV VLPs improve immunogenicity and protection against EMCV infection in mice and swine?
Does immunization with EMCV VLPs improve immunogenicity and protection against EMCV infection in mice and swine?
Recombinant EMCV VLPs demonstrate immunogenicity and protective efficacy in animal models, suggesting potential as a new vaccine candidate for pig farms.
Supports VLP vaccine candidacy for EMCV; leaves open efficacy and safety in commercial swine.
BACKGROUND: In this study, porcine encephalomyocarditis virus (EMCV) virus-like particles (VLPs) were generated using a baculovirus expression system and were tested for immunogenicity and protective efficacy in vivo. RESULTS: VLPs were successfully generated from Sf9 cells infected with recombinant baculovirus and were confirmed to be approximately 30-40 nm by transmission electron microscopy (TEM). Immunization of mice with 0.5 μg crude protein containing the VLPs resulted in significant protection from EMCV infection (90%). In swine, increased neutralizing antibody titers were observed following twice immunization with 2.0 μg crude protein containing VLPs. In addition, high levels of neutralizing antibodies (from 64 to 512 fold) were maintained during a test period following the second immunization. No severe injection site reactions were observed after immunization and all swine were healthy during the immunization period. CONCLUSION: Recombinant EMCV VLPs could represent a new vaccine candidate to protect against EMCV infection in pig farms.
No takes yet. Share an insight, caveat, or question.
Jeoung et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: